All In Biotech

Drug Trial Radar · NCT06720597

EndoPAT Device for Endothelial Dysfunction in ED

Utilizing EndoPAT Device for Endothelial Dysfunction Assessment in Erectile Dysfunction and Hormonal Therapy

Last checked: Nov 20, 2026Latest source record: Feb 2, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

120

Planned (sponsor's estimate)

Start

Aug 13, 2025

Primary completion

Jan 2027

Study completion Jan 2027

Sponsor

Lead sponsor
University of California, IrvineAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 6, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Diagnostic
FDA-regulated drug
No
Who can join
Male only, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

To assess endothelial dysfunction in young men (aged 30-50) with vasculogenic ED identified through penile Doppler ultrasound. To evaluate changes in endothelial function using EndoPAT before and 3-6 months after daily low-dose phosphodiesterase type 5 (PDE5) inhibitor therapy. To investigate endothelial function alterations in hypogonadal patients before and 3-6 months after initiating testosterone (T) therapy

Conditions

  • Erectile Dysfunction
  • Hypogonadism, Male
  • Endothelial Dysfunction

Interventions

  • Daily low-dose PDE5 inhibitor therapyDrug

    Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention in each arm.

  • Testosterone therapy as per clinical guidelines.Drug

    Neither arm of the study includes a control group, and the two interventions will not be compared directly. The primary objective is to evaluate endothelial function using the EndoPAT device at baseline, 3 months, and 6 months following the intervention.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Endothelial Function as Measured by Reactive Hyperemia Index (RHI)Time frame: At baseline, 3 months, and 6 months post-intervention

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UCI Urology | Men's Health Center

    Newport Beach, California · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.